公开(公告)号：EP0846702B1

公开(公告)日：2009-03-11

申请号：EP97120800.4

申请日：1997-11-27

申请人： Merck Patent GmbH

发明人： Goodman, Simon L. ,  Mehta, Raj ,  Diefenbach, Beate ,  Cullen, Eilish ,  Güssow, Detlev ,  Brown, Alex

IPC分类号： C07K14/705 ,  C12N15/12

CPC分类号： C07K14/70557 ,  C12N2799/026

公开(公告)号：EP0846702A2

公开(公告)日：1998-06-10

申请号：EP97120800.4

申请日：1997-11-27

申请人： MERCK PATENT GmbH

发明人： Goodman, Simon L. ,  Mehta, Raj ,  Diefenbach, Beate ,  Cullen, Eilish ,  Güssow, Detlev ,  Brown, Alex

IPC分类号： C07K14/705

CPC分类号： C07K14/70557 ,  C12N2799/026

摘要： The invention relates to a novel purified recombinant α V β 3 adhesion receptor which shows an unimpaired ligand binding activity, and a process for preparing said soluble non-membrane bound receptor in excellent yields by recombinant techniques using a baculovirus-insect cell expression system.
The so-synthesized soluble receptor may be used very easily as screening tool for new therapeutic compounds which may inhibit the natural α V β 3 adhesion receptor. Such therapeutic compounds which can be discovered very easily, fast and without health risk by means of the souluble receptors according to the invention may be, for example, RGD peptides or non-peptidic compounds mimicking the natural ligand epitopes.
The invention relates, furthermore, to a corresponding process for preparing recombinant full-length α V β 3 adhesion receptor in excellent yields, additionally using detergents to solve the membrane bound receptor from the surface of the host cell.

摘要翻译： 本发明涉及一种新型纯化的重组αvβ3粘附受体，其显示出未受损的配体结合活性，以及​​通过使用杆状病毒 - 昆虫细胞表达系统的重组技术以优异产率制备所述可溶性非膜结合受体的方法。 如此合成的可溶性受体可以非常容易地用作可能抑制天然α-β3粘附受体的新的治疗化合物的筛选工具。 可以通过根据本发明的灵魂受体非常容易，快速且没有健康风险发现的这种治疗化合物可以是例如RGD肽或模仿天然配体表位的非肽化合物。 此外，本发明还涉及以优异的产率制备重组全长αVβ3粘附受体的相应方法，另外使用洗涤剂从宿主细胞表面解决膜结合受体。

公开(公告)号：EP0846702A3

公开(公告)日：2001-07-18

申请号：EP97120800.4

申请日：1997-11-27

申请人： MERCK PATENT GmbH

发明人： Goodman, Simon L. ,  Mehta, Raj ,  Diefenbach, Beate ,  Cullen, Eilish ,  Güssow, Detlev ,  Brown, Alex

IPC分类号： C07K14/705

CPC分类号： C07K14/70557 ,  C12N2799/026

摘要： The invention relates to a novel purified recombinant α V β 3 adhesion receptor which shows an unimpaired ligand binding activity, and a process for preparing said soluble non-membrane bound receptor in excellent yields by recombinant techniques using a baculovirus-insect cell expression system. The so-synthesized soluble receptor may be used very easily as screening tool for new therapeutic compounds which may inhibit the natural α V β 3 adhesion receptor. Such therapeutic compounds which can be discovered very easily, fast and without health risk by means of the souluble receptors according to the invention may be, for example, RGD peptides or non-peptidic compounds mimicking the natural ligand epitopes. The invention relates, furthermore, to a corresponding process for preparing recombinant full-length α V β 3 adhesion receptor in excellent yields, additionally using detergents to solve the membrane bound receptor from the surface of the host cell.